Business Wire

Chinese Service Providers Built Over 800 Alipay Mini Programs Within Two Months, Each Drawing Over 10,000 Active Users

Share

Alipay, the world’s leading open digital lifestyle platform operated by Ant Group, today unveiled data showing how China’s service industry is embracing the power of digital technology as it continues to recover from the impact of COVID-19 and prepare for the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005309/en/

Simon Hu, Chief Executive Officer at Ant Group, at Alipay’s Partner Conference in Hangzhou, China on May 20, 2020 (Photo: Business Wire)

Simon Hu, Chief Executive Officer at Ant Group, at Alipay’s Partner Conference in Hangzhou, China on May 20, 2020 (Photo: Business Wire)

Service providers in China have built over 800 Alipay mini programs in just two months, each with more than 10,000 monthly active users (MAU), since Alipay first announced a plan to help 40 million service providers go digital. By leveraging Alipay’s AI-driven incentive programs, service providers that consistently improve users’ experience on the platform can receive optimized user traffic.

“The service industry is at a critical juncture in its digital journey, and Alipay continues to play an important role in facilitating this transformation,” said Simon Hu, Ant Group’s Chief Executive Officer. “This pivot to digital is expected to drive significant growth for the internet sector in the next decade.”

“We are committed to opening up our platform and collaborating with our partners to support more service providers as they continue to go digital,” Simon said.

On-demand logistics services company Huolala underwent a digital transformation shortly after business plunged 93% during the COVID-19 outbreak. The Shenzhen-based company rapidly developed and deployed an Alipay mini program to make its delivery services available to users of the app.

Today, Huolala continues to improve customer experience on the platform by optimizing and adding new services to its Alipay mini program. As a result, the company’s mini program has received more optimized user traffic. Winnie Xue, Business Development Director at Huolala, said, “Alipay’s mini programs can also run seamlessly on other major platforms within the Alibaba ecosystem, such as AutoNavi and Tmall, enabling service providers like us to reach more users without incurring additional development costs.”

As a result, Huolala’s daily transactions via Alipay soared 667% from March to April, representing a year-on-year surge of 142%.

Managers of more than 1,000 scenic destinations, as well as 300 city administrators in China, have also set up Alipay mini programs so users can access services such as carpark payments and making hospital or viral test appointments, without having to installing separate apps for each service.

As of May 20, city administrators in more than 100 cities across China have also issued consumption coupons via Alipay mini programs, with 90% of the beneficiaries being SMEs, such as milk tea shops, restaurants and hair salons.

Alipay is also working with Independent Software Vendors (ISVs), enabling them to support service providers on their digital transformation journey. ISVs package Alipay’s technologies into solutions to meet the needs of specific industries and use cases, ranging from consumer retail, food-and-beverage, hotels-and-accommodations, transportation to medical services. Service providers going digital has also brought about new growth opportunities for ISVs.

Case studies of ISVs supporting service providers to go digital on Alipay

  1. ISV Qimaiyunshang helps catering businesses develop Alipay mini programs that enable customers to scan a QR code to order food, or wait in a virtual queue via the Alipay app. It saw a surge of 20,000 new catering business clients in the past month due to increasing demand from restaurant owners for digital services.
  2. Quick Ying Technology, an ISV focused on the tourism sector, supported managers of 50 scenic destinations to launch their Alipay mini programs since mid-February, and has hired an additional 30% more people to cope with the surge in clients.

About Alipay

Alipay is the world's leading open digital lifestyle platform operated by Ant Group. In 2004, Alipay launched as an escrow service to address the issue of trust between online buyers and sellers in the early days of e-commerce in China. Continuously innovating to bring mobile payment to the world, Alipay serves more than 1.2 billion users worldwide together with its global e-wallet partners as of June 30, 2019.

Alipay has evolved from a payment tool to become a one-stop digital lifestyle platform. Through an open platform strategy, it introduces service providers from sectors such as local living, public services, and financial services, to bring consumers a more comprehensive experience. Along the way, it helps merchants digitalize their operations, promoting digital transformation in the service industry.

Alipay actively shares its financial technology experience with overseas partners, in order to bring inclusive financial services to the world. Working with more than 250 overseas financial institutions, Alipay created online payment channels for buyers and sellers in more than 200 countries and regions. When Chinese people travel abroad, they can pay directly using their mobile phones, and receive dedicated local merchant services through Alipay. These services have been introduced in 56 countries and regions. Tax reimbursement via Alipay is supported in 35 countries and regions, and Alipay supports 27 different currencies. In addition, foreign tourists and foreigners living in China can also use Alipay for mobile payments in the country.

Contact information

For media queries
Ant Group
Mr. Le Shen
Email: shenle.sl@antfin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom